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Abstract
Background: Neuroinflammation has been implicated in various brain pathologies characterized by hypoxia and ischemia.
Astroglia play an important role in the initiation and propagation of hypoxia/ischemia-induced inflammation by secreting
inflammatory chemokines that attract neutrophils and monocytes into the brain. However, triggers of chemokine up-regulation
by hypoxia/ischemia in these cells are poorly understood. Hypoxia-inducible factor-1 (HIF-1) is a dimeric transcriptional factor
consisting of HIF-1α and HIF-1β subunits. HIF-1 binds to HIF-1-binding sites in the target genes and activates their transcription.
We have recently shown that hypoxia-induced expression of IL-1β in astrocytes is mediated by HIF-1α. In this study, we
demonstrate the role of HIF-1α in hypoxia-induced up-regulation of inflammatory chemokines, human monocyte
chemoattractant protein-1 (MCP-1/CCL2) and mouse MCP-5 (Ccl12), in human and mouse astrocytes, respectively.
Methods: Primary fetal human astrocytes or mouse astrocytes generated from HIF-1α+/+ and HIF-1α+/- mice were subjected
to hypoxia (<2% oxygen) or 125 μM CoCl2 for 4 h and 6 h, respectively. The expression of HIF-1α, MCP-1 and MCP-5 was
determined by semi-quantitative RT-PCR, western blot or ELISA. The interaction of HIF-1α with a HIF-1-binding DNA sequence
was examined by EMSA and supershift assay. HIF-1-binding sequence in the promoter of MCP-1 gene was cloned and
transcriptional activation of MCP-1 by HIF-1α was analyzed by reporter gene assay.
Results: Sequence analyses identified HIF-1-binding sites in the promoters of MCP-1 and MCP-5 genes. Both hypoxia and HIF-
1α inducer, CoCl2, strongly up-regulated HIF-1α expression in astrocytes. Mouse HIF-1α+/- astrocytes had lower basal levels of
HIF-1α and MCP-5 expression. The up-regulation of MCP-5 by hypoxia or CoCl2 in HIF-1α+/+ and HIF-1α+/- astrocytes was
correlated with the levels of HIF-1α in cells. Both hypoxia and CoCl2 also up-regulated HIF-1α and MCP-1 expression in human
astrocytes. EMSA assay demonstrated that HIF-1 activated by either hypoxia or CoCl2 binds to wild-type HIF-1-binding DNA
sequence, but not the mutant sequence. Furthermore, reporter gene assay demonstrated that hypoxia markedly activated MCP-
1 transcription but not the mutated MCP-1 promoter in transfected astrocytes.
Conclusion: These findings suggest that both MCP-1 and MCP-5 are HIF-1 target genes and that HIF-1α is involved in
transcriptional induction of these two chemokines in astrocytes by hypoxia.
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Background
Ischemic brain damage, including that caused by stroke
and trauma, elicits inflammation in the injured areas [1-
3]. A number of inflammatory mediators are expressed in
the brain in response to ischemia and hypoxia [1-4].
Hypoxia or ischemia stimulates the expression of inflam-
matory cytokines (IL-1β, TNF-α), chemokines (IL-8, MCP-
1/CCL2) and adhesion molecules (ICAM-1) in the brain
and in cultured astrocytes and brain endothelial cells [5-
10]. These inflammatory mediators play a critical role not
only in the initiation and propagation of ischemica/
hypoxia-evoked neuroinflammation but also in the reso-
lution of brain damage [1-4]. However, triggers of inflam-
matory chemokine up-regulation by hypoxia/ischemia in
these cells are poorly understood. We have recently shown
that hypoxia-stimulated IL-1β expression in astrocytes is
mediated by hypoxia-inducible factor-1α (HIF-1α) [11].
Hypoxia-inducible factor-1 (HIF-1) is a transcription fac-
tor that plays a central role in cellular and systemic home-
ostatic responses to hypoxia [12-14]. HIF-1 is a
heterodimeric protein complex consisting of two subu-
nits, the redox-sensitive HIF-1α (120–130 kD), which is
unique to HIF-1, and the constitutively expressed HIF-1β
(91–94 kD), a common partner for many other transcrip-
tion factors [12-14]. Both subunits are necessary for DNA
binding and activation of HIF-1 target genes [15,16]. Sev-
eral HIF-1α isoforms have been found, including HIF-2α
and HIF-3α, both of which have significant homologies to
HIF-1α [13,14,17]. Although these HIF-1 isoforms may
also contribute to the response to hypoxia, HIF-1α is con-
sidered the major regulator of O2-tension sensitive genes
in cells [12,13]. Decrease in cellular O2 tension or the
presence of CoCl2 or desferroxamine leads to elevation of
HIF-1α expression, whereas carbon monoxide and nitric
oxide inhibit HIF-1 activation [18-20]. HIF-1α is cytosolic
and degraded by ubiquitin-proteasome pathway [21,22]
via binding of von Hippel-Lindau tumor suppressor pro-
tein to the oxygen-dependent degradation domain [23].
Hypoxia induces HIF-1α expression in tissues and cul-
tured cells [12,13,24]. The length of hypoxic stress deter-
mines HIF-1α half-life upon reoxygenation. During
hypoxia, HIF-1α is stabilized and dimerized with HIF-1β,
and the complex is translocated into nucleus where it
binds to hypoxia-responsive elements in the promoters or
enhancers of the target genes, such as the genes encoding
erythropoetin (EPO), glucose transporters, glycolytic
enzymes, heme oxygenase-1, inducible nitric oxide syn-
thase, transferin, and vascular endothelial growth factor
(VEGF) [12-14,25,26]. The consensus DNA sequence for
HIF-1 binding in the hypoxia-response element is 5'-[A/
G]CGTG-3' flanked with or without a second consensus
site 5'-[A/C]ACAG-3' [12]. Mutations of the consensus
sequences result in loss of HIF-1 binding and transcrip-
tional response of the genes to hypoxia [12]. In vitro expo-
sure to CoCl2  or iron chelator deferoxamine under
normoxic conditions produces a hypoxia-mimetic effect
with up-regulation of HIF-1α and target gene expression
[12-14,26]. Cobalt chloride (CoCl2) increases erythropo-
etin (EPO) production in vitro [27] and in vivo [28] under
normoxic conditions and was once given to human
patients to treat anemia.
Astroglial cells are the most abundant cells in the brain
and serve as an important source of inflammatory media-
tors during the course of neuroinflammation [1-3]. Astro-
cytes subjected to in vitro ischemia/hypoxia produce a
large amount of chemoattractant MCP-1 which is 30-time
higher than that secreted by human brain endothelial
cells subjected to the same treatment [6]. MCP-1 is a
potent chemokine and directs the transmigration of
blood-borne monocytes/macrophages across the blood-
brain barrier (BBB) into the inflammatory sites in the
brain [1-3]. Mouse monocyte chemoattractant protein-5
(MCP-5), known as chemokine (C-C motif) ligand 12
(Ccl12) or small inducible cytokine A12 (Scya12), is also
a potent monocyte chemokine homologous to human
MCP-1 with 66% amino acid identity [29]. This study
shows that HIF-1α is involved in transcriptional activa-
tion of MCP-1 and MCP-5 expression stimulated by
hypoxia in human and mouse astrocytes, respectively.
Materials and methods
Animal use and genotyping
All procedures involving animals were approved by the
Animal Care and Use Committee of the NRC-Institute for
Biological Science (NRC-IBS). HIF-1α+/-  heterozygous
mice were obtained from the Center for Transgene Tech-
nology and Gene Therapy, Flanders Interuniversity Insti-
tute for Biotechnology, Belgium [30] and bred in the
Animal Facility at the NRC-IBS. Offspring from mating
between HIF-1α+/+ and HIF-1α+/- mice or between HIF-
1α+/- and HIF-1α+/- mice was genotyped by polymerase
chain reaction (PCR) as described [30]. HIF-1α-/- is lethal
in embryonic development [30]. To identify heterozygous
(HIF-1α+/-) or wild (HIF-1α+/+) littermates, genomic DNA
samples of the offspring were analyzed at 7 days of age. In
brief, tissues obtained by tail clipping were digested at
55°C for 18 h in a lysis buffer containing 1 mg/ml protei-
nase K, 0.5% lauryl sulfate (SDS), 100 mM NaCl, 50 mM
Tris-HCl (pH8.0), and 7.5 mM EDTA (pH 8.0) (Sigma,
Oakville, ON). Genomic DNA was extracted using phe-
nol-isoamyl alcohol and precipitated with isopropanol
(Invitrogen, Burlington, ON). DNA pellets were resus-
pended in TE buffer containing 10 mM Tris-HCl (pH 8.0)
and 1 mM EDTA (pH 8.0). Genomic DNA was amplified
in a single tube for 35 PCR cycles using a set of three spe-
cific primers (HIF700, HIF960, and NEO187) (Table 1)
[30]. PCR, performed as described [11], generated a 380
bp DNA fragment (HIF960 and NEO187 primers) and a
230 bp fragment (HIF700 and HIF960 primers) for heter-Journal of Neuroinflammation 2007, 4:12 http://www.jneuroinflammation.com/content/4/1/12
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ozygous mice (HIF-1α+/-) and only a 230 bp fragment
(HIF700 and HIF960 primers) for wild-type mice (HIF-
1α+/+).
Cell cultures
Primary mouse astrocyte cultures were generated from 7-
day old HIF-1α+/+ and HIF-1α+/- mice using a modified
technique previously described [31]. Briefly, mouse
brains were dissected under sterile conditions and menin-
geal tissues were removed. The minced brain tissues were
mechanically dissociated by passing through needles of
increasing gauge (18, 23, and 25) and subsequent 15-
minute exposure to dispase (3 mg/ml). The resulting cell
suspensions were passed through a sterile nylon mesh
(Nitex) sieve (32 μm pore size) into Dulbecco's modified
Eagle's medium (D-MEM) (Invitrogen, Burlington, ON).
After centrifugation at 1200 rpm for 10 minutes at room
temperature, the cells were seeded into culture dishes
coated with sterile poly-lysine. The cells were cultured in
an atmosphere of 5% CO2/95% air at 37°C in D-MEM
containing 4.5 g/L glucose, 2 mM glutamine, 25 μg/ml
gentamycin (Invitrogen, Burlington, ON), and 10% fetal
bovine serum (FBS, HyClone, Logan, UT, U.S.A.). The
purity of the astrocyte cultures was determined by staining
with the specific astrocyte marker, glial fibrillary acidic
protein (GFAP) [6-8,11]. More 95% of the cells in cultures
were GFAP-positive (data not shown). Both HIF-1α+/+ and
HIF-1α+/- astrocyte cultures showed similar morphology
and GFAP-staining. Passages 3–6 of the cultures were used
at 80%–90% confluence. Immortalized HIF-1α+/+  and
HIF-1α+/- astrocyte cultures [11] were used in some of the
experiments (western blot, EMSA and supershift assays).
The morphology and immunochemical characteristics
(100% immuno-positive for GFAP), and culture condi-
tions used for immortalized cells were the same for the
primary astrocytes, except that passages 11–14 were used
in the western blot, EMSA and supershift assays.
Fetal human (10–18 weeks of gestation) astrocyte (FHAs)
cultures were generously provided by Dr. J. Antel at the
Montreal Neurological Institute, Montreal, Quebec. The
use of primary fetal human astrocytes was approved by
the Research Ethics Board of National Research Council of
Canada. The FHAs cultures were prepared using the same
protocol as described above [31] and grown using the
same media and culture conditions as the mouse astro-
cytes [8,11]. More than 95% of the cells in FHAs cultures
were stained positive for GFAP (data not shown).
In vitro hypoxia
Cells were exposed to in vitro hypoxia in an anaerobic
chamber (Anaerobic System Model 1024, Forma Scien-
tific, Canada) equipped with a humidified, temperature
controlled incubator as described [7,8]. The cells were
washed once in Hank's balanced salt solution (HBSS)
(Sigma, Oakville, ON) and serum-free D-MEM was added
to the cells. For mouse astrocytes, hypoxic incubation was
performed at < 2% O2 in the anaerobic chamber at 37°C
for 6 h. Alternatively, cells were exposed to 125 μM cobalt
chloride (CoCl2) (Sigma) for 6 h at 37°C. Media and cells
were harvested for MCP-5 ELISA assay, RT-PCR detection
of HIF-1α and MCP-5 mRNA expression, and western blot
analysis of HIF-1α, respectively. For FHAs, both hypoxic
treatment and cobalt chloride (CoCl2) exposure were
instead for 4 h, since human astrocytes are more sensitive
to hypoxia than mouse astrocytes. The media and cells
were harvested for MCP-1 ELISA, RT-PCR and EMSA,
respectively.
Semi-quantitative RT-PCR
Total RNA was isolated from astrocytes using Trizol (Inv-
itrogen) according to the manufacturer's protocol. Synthe-
sis of first-stand cDNA was performed by reverse
transcription (RT) for 1 h at 42°C as described [7]. PCR
primers were designed according to published sequences
in the GenBank (Table 1). PCR amplifications were car-
ried out in a final volume of 25 μl containing 2.5 μl of 10×
reaction buffer, 1.5 μl of 25 mM MgCl2, 0.5 μl of 10 mM
dNTP, 0.25 μl of Taq DNA polymerase (Promega, Madi-
son, WI) (5 unit/μl), 1.0 μl of each 10 μM primer, and 2
Table 1: PCR primer sequences
Gene Primer sequences
HIF-1α 5'-GAT CGC CCT ACG TGC TGT CTC A-3'
5'-GAT CTG AGA CAG CAC GTA GGG C-3'
MCP-1 5'-GCTCGCTCAGCCAGATGCAAT-3'
5'-TGGGTTGTGGAGTGAGTGTTC-3'
MCP-5 5'-CCT GTG GCC-TTG GGC CTC AA-3'
5'-GAG GTG CTG ATG TAC CAG TTG G-3'
β-Actin 5'-GTC ACC CAC ACT GTG CCC ATC T-3'
5'-ACA GAG TAC TTG CGC TCA GGAG-3'
HIF 700 5'-CAA GCA TTC TTA AAT GTG GAG CTA TCT-3'
HIF 960 5'-TTG TGT TGG GGC AGT ACT GGA AAG ATG-3
NEO187 5'-GCC GAG GCA AGA AAC CAC CGG GGA AGC-3'Journal of Neuroinflammation 2007, 4:12 http://www.jneuroinflammation.com/content/4/1/12
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μl cDNA. All amplifications were done using a heating for
5 min at 94°C, denaturation step at 94°C for 60 sec,
annealing step at 60°C for 60 sec, and polymerization
step at 72°C for 60 sec, and were carried out for 35 cycles.
All the genes were linearly amplified during the 35 PCR
cycles determined as described [7] (data not shown). The
resulting PCR was electrophoresed on 1.2% agarose gels
in Tris-borate buffer containing 0.5 μg/ml ethidium bro-
mide (Sigma), and then photographed. The PCR gener-
ated a 504 DNA fragment for human and mouse HIF-1α,
a 312 bp fragment for mouse MCP-5, a 257 bp fragment
for human MCP-1, and a 421 bp fragment for β-actin of
human and mouse. Signal intensity of the products was
quantified by calculating the integrated volume of the
band with a Computing Laser Densitometer (Model
300A, Molecular Dynamic, CA) and analyzed using
ImageQuaNT, version 4.1 software (Molecular Dynamics,
CA). Obtained values were expressed as percentages of the
internal controls.
ELISA
The levels of immunoreactive MCP-1 and MCP-5 released
from astrocytes into culture media were measured by the
enzyme-linked immunosorbent assays (ELISA), using
commercial MCP-1 (ID Labs Inc., London, ON) and
MCP-5 kits (Amersham Biosciences, Montreal, PQ),
respectively. Prior to ELISA assays, aliquots of culture
media collected and stored at -80°C were thawed and cen-
trifuged at 14,000 rpm for 5 min at 4°C before the assays
to remove cell debris. The assays were performed as
instructed by the manufacturers.
Western blot
Mouse HIF-1α+/+ and HIF-1α+/- astrocytes were exposed to
hypoxia or 125 μM CoCl2 for 6 h. Nuclear extracts were
prepared from the treated-cells as described [11]. Equal
amounts of nuclear protein (20 μg) from each sample
were resolved on a 10% SDS-PAGE gel [11]. After the pro-
teins were resolved on the gel and blotted to nitrocellulose
membrane, a rabbit anti-HIF-1α antibody (CAT# NB
100–654, Novus Biologicals Inc., Littleton, CO) and a sec-
ondary HRP-conjugated goat anti-rabbit IgG antibody
(CAT# sc-2004, Santa Cruz Biotech Inc., Santa Cruz, CA)
were used sequentially at 1:1000 and 1:3000 dilutions,
respectively, as described [11]. ECL Plus reagents (Amer-
sham Biosciences Inc) were then applied to the mem-
branes and the membranes were exposed to X-ray film for
30 min to detect the levels of HIF-1α protein in cells
exposed to hypoxia or 125 μM CoCl2.
Electrophoretic mobility shift assay (EMSA) and supershift 
assay
Nuclear extracts were prepared from mouse astrocytes
treated with hypoxia or 125 μM CoCl2 for 6 h using a
modified protocol as described previously [8,11]. The
protein concentrations of the nuclear extracts were deter-
mined using the Bradford assay (BioRad Laboratories,
Hercules, CA). For the EMSA, a typical double-stranded
consensus oligonucleotide for HIF-1 binding (5'-TCTG-
TACGTGACCACACTCACCTC-3') and a mutant DNA
sequence (5'-TCTGTAAAAGACCACACTCACCTC-3')
[15,16] were purchased from Santa Cruz Biotech Inc (CAT
# sc-2625, Santa Cruz, CA) and end-labeled with γ[32P]-
ATP (Mandel/NEN Life Science, Guelph, ON). Nuclear
proteins (5 μg) were incubated with 2 μg poly-d [I-C]
(Amersham Biosciences, Montreal, Quebec) in DNA
binding buffer containing 20 mM HEPES (pH 7.9), 0.2
mM EDTA, 0.2 mM EGTA, 100 mM KCl, 5% glycerol, and
2 mM DTT (Sigma) for 10 min at room temperature.
Labeled probe (2 ng) was then added to the reaction mix-
ture and incubated for 30 min at room temperature in a
final volume of 20 μl. For supershift assay, 4 μg rabbit
anti-HIF-1α antibody (CAT# NB 100–654, Novus Biolog-
icals Inc., Littleton, CO) was added to the reactions. DNA-
protein complexes were separated from unbound DNA on
native 5% polyacrylamide gels [8]. The gels were dried
and exposed to an X-ray film.
Luciferase reporter gene assay
A 98 bp wild-type HIF-1 binding sequence from human
MCP-1 promoter region (GenBank Accession
#AY357296, 2946nt 5'-AAGCAGACGTGGTAC-
CCACAGTCTTGCTTTAACG
CTACTTTTCCAAGATAAGGTGACTCAGAAAAG-
GACAAGGGGTGAGCCCAACCACACAGCTGCT-3'
3043nt) was PCR-amplified from genomic DNA isolated
from FHAs using a pair of primers (sense primer 5'-gggg-
taccATCCAAGCAGACGTGGTACC-3' and antisense
primer 5'-gaagatctGAGCAGCAGCTGTGTGGTTG-3'). The
bold-capital letter and underlined sequences are consen-
sus HIF-1-binding sites, and the underlined small-letter
sequences in the sense and anti-sense primers are KpnI
and BglII cutting sites, respectively. The PCR fragment was
cleaved with KpnI and BglII (Invitrogen) and cloned into
a luciferase yellow reporter gene vector pGL3-promoter
vector (Promega Madison, WI) cleaved with the same
enzymes. The construct pGL3/MCP1w carrying the wild-
type sequence was sequenced to confirm accuracy. A
mutant sequence (5'-AAGCAGATTTGGTACCCT-
TAGTCTTGCTTTAACGCTACTTTTCC AAGATAAGGT
GACTCAGAAA AGGACAAGGG GTGAGCCCAA
CCACAAGGCTGCT-3') was generated by genomic PCR
using a pair of primers (5'-ggggtacc ATCCAAGCAGATTT-
GGTACCCTTAGTCTTGCTTT-3', and 5'-gaagatctGAG-
CAGC AGCCTTGTGGTTGGGGC-3'), cleaved by KpnI
and BglII and cloned into the pGL3 promoter vector. The
construct pGL3/MCP1m was sequenced to confirm accu-
racy. The luciferase yellow reporter gene assay was per-
formed as described previously [11]. Briefly, FHAs grown
in 24-well plates to 90% confluence were transfected withJournal of Neuroinflammation 2007, 4:12 http://www.jneuroinflammation.com/content/4/1/12
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0.5 μg of either an empty pGL3 promoter vector or the
vectors containing the wild-type or the mutant HIF-1-
binding sequence for 2.5 hours using SuperFect™ (QIA-
GEN, Mississauga, ON) as per manufacturer's protocol.
The cells were then washed and recovered in complete
media for 16 h at 37°C. The media were then removed,
cells washed once with HBSS, and plain D-MEM was
added. The cells were then exposed to hypoxia for 4 h at
37°C. At the end of experimental treatments, the media
were removed, and cells were washed twice with Ca2+/
Mg2+-free HBSS (Sigma) and then lysed in 50 μl of cell
lysis reagent (Promega, Madison, WI). Reporter gene
activity using luciferese assays was determined using a
Promega kit. The luciferase assay reagent containing D-
luciferin was added to aliquots of cell lysates and chemi-
luminescence was measured at 25°C using a chemilumi-
nescence counter (MicroBeta™ TriLux, Wallac Oy,
Finland). Controls for the transfection efficiency were
done by simultaneous transfection of CMV β-galactosi-
dase (Promega, Madison, WI). The transfection efficiency
was about 55% (data not shown). Total cell protein was
determined in each sample using a Bradford assay (Bio-
Rad Laboratories, Hercules, CA). Light units emitted from
samples were read against a standard curve (Recombinant
Luciferase, Promega, Madison, WI) and normalized to
protein levels in cell lysates.
Statistical analysis
Each assay had at least two replicates and each experiment
or assay was performed at least three times and represent-
ative examples are shown. Data are reported as means ±
SD, analyzed by one-way ANOVA and p < 0.05 is consid-
ered significant.
Results
HIF-1-binding regions in MCP-1 and MCP-5 genes
Our recent work demonstrated that transcriptional activa-
tion of IL-1β in human and mouse astrocytes during
hypoxia is mediated by HIF-1α [11]. To evaluate whether
the expression of other inflammatory cytokines and
chemokines would be regulated by HIF-1α, we analyzed
genomic DNA sequences of human MCP-1 (GenBank
Accession #AY357296) and mouse MCP-5 genes (Gen-
Bank Accessions # AC012294, NC_000077). Several HIF-
1-binding sites were identified in the promoter regions of
MCP-1 and MCP-5 genes (Table 2). The presence of HIF-
1-binding sites provides the molecular basis for a hypoth-
esis that HIF-1 regulates transcriptional activation of
MCP-1 and MCP-5 expression under hypoxic conditions.
MCP-5 in mouse astrycotes
To study the role of HIF-1α in transcriptional regulation
of monocyte chemokine MCP-5, primary astrocyte cul-
tures with HIF-1α+/- or HIF-1α+/+ genotype were generated
from HIF-1α+/- heterozygous and wild-type mice, respec-
tively [30]. The expression level of HIF-1α mRNA in HIF-
1α+/- cells was about 50% of that in HIF-1α+/+ astrocytes
(Fig. 1). The exposure to a-6 h hypoxia resulted in up-reg-
ulation of HIF-1α mRNA in both HIF-1α+/- and HIF-1α+/+
astrocytes (Fig 1). The level of HIF-1α mRNA in HIF-1α+/
+ cells exposed to hypoxia increased ~50% above the level
in normoxic HIF-1α+/+ controls (Fig. 1). However, the rel-
ative increase of HIF-1α mRNA in HIF-1α+/- cells (~140%)
subjected to hypoxia was higher than that in HIF-1α+/+
cells (~55%) compared to its relevant control (Fig. 1). The
level of HIF-1α mRNA expression in hypoxia-treated HIF-
1α+/- cells was only ~20% less than that in hypoxia-treated
wild-type cells (Fig. 1). Similar pattern was also observed
for HIF-1α protein as we reported previously [11]. These
results suggest that HIF-1α+/- cells, although having one
copy of HIF-1α allele, responded to hypoxia at a relative
higher magnitude than HIF-1α+/+  cells exposed to
hypoxia.
Both MCP-5 mRNA and protein were detected in astro-
cytes under normoxic conditions (Fig. 2); however, the
basal levels of MCP-5 mRNA and protein in HIF-1α+/-
astrocytes were about 50% lower than those in HIF-1α+/+
cells (Fig. 2). Hypoxia resulted in a significant up-regula-
tion of MCP-5 mRNA in both HIF-1α+/- and HIF-1α+/+
astrocytes. The levels of hypoxia-induced MCP-5 mRNA
in HIF-1α+/- cells reached the levels of normoxic HIF-1α+/
+  cells (Fig. 2A); nevertheless, the levels of hypoxia-
induced MCP-5 mRNA in HIF-1α+/- cells were still only
50% of those in hypoxia-treated HIF-1α+/+ cells. Under
normaxic condition, the levels of immunoreactive MCP-5
quantified by ELISA were lower in HIF-1α+/- astrocyte
media than those in the media obtained from HIF-1α+/+
cells (Fig. 2B). Hypoxia strongly stimulated the release of
MCP-5 into culture media in both cell types; however,
MCP-5 levels in HIF-1α+/- cells were only about 50% of
the wild-type cells (Fig. 2B). These results suggest that the
MCP-5 stimulation by hypoxia correlated with the levels
of HIF-1α in cells.
The exposure to cobalt chloride or iron chelator desferox-
iamine under normoxic conditions triggers transcrip-
tional events that mimic a hypoxic condition by
increasing the expression of HIF-1α and its target genes
[12-14,26-28]. Exposure of HIF-1α+/- and HIF-1α+/+ astro-
cytes to 125 μM CoCl2 for 6 h induced a hypoxia-like
response characterized by increased levels of HIF-1α
mRNA (Fig. 3). CoCl2 strongly up-regulated HIF-1α in
HIF-1α+/- astrocytes, reaching the levels of mRNA in HIF-
1α+/+ astrocytes (Fig. 3A). Both CoCl2 and hypoxia up-reg-
ulated the levels of HIF-1α protein in HIF-1α+/- cells (Fig.
3B). CoCl2 significantly up-regulated MCP-5 mRNA in
HIF-1α+/- cells (Fig. 4A) and the release of immunoreac-
tive MCP-5 protein from the cells (Fig. 4B). The CoCl2-
induced up-regulation of HIF-1α in HIF-1α+/+ cells (Fig.Journal of Neuroinflammation 2007, 4:12 http://www.jneuroinflammation.com/content/4/1/12
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3A) was less potent than that induced hypoxia (Fig. 1).
Therefore, MCP-5 expression in HIF-1α+/+ cells exposed to
CoCl2 was not significantly affected (Fig. 4). The presence
of HIF-1-binding sites in the promoter of MCP-5 gene and
the observation that the expression of MCP-5 correlated
with the levels of HIF-1α suggest that HIF-1α is involved
in transcriptional regulation of MCP-5 expression in
mouse astrocytes.
MCP-1 in fetal human astrocytes (FHAs)
As shown previously, HIF-α was strongly up-regulated in
FHAs at both mRNA and protein levels in response to 4 h
hypoxia or 125 μM cobalt chloride [11]. Both hypoxia
and cobalt chloride also strongly up-regulated the expres-
sion of MCP-1 mRNA in FHAs as compared to controls
(Fig. 5A). The level of immunoreactive MCP-1 released by
hypoxia-treated (14015 ± 2770 pg/ml) and CoCl2-treated
FHAs (15702.09 ± 1137.85) was about two-fold higher
than that secreted by control FHAs (7092 ± 1920 pg/ml)
(p < 0.05) (Fig. 5B).
HIF-1 interacts with HIF-1-binding DNA sequence
Since HIF-1-binding sequences are identified in the pro-
moter regions of MCP-1 and MCP-5 genes (Table 2), the
binding of HIF-1 protein complex to a typical HIF-1-bind-
ing consensus DNA sequence [15,16] was examined by
EMSA as described in the Materials and methods. HIF-1
protein complex in nuclear extracts prepared from
hypoxia-or cobalt chloride-treated mouse astrocytes was
capable of binding the wild-type DNA sequence but not
the mutant sequence (Fig. 6A). More HIF-1/DNA complex
was seen in HIF-1α+/+ cells (lanes #2 & 3) than that in HIF-
1α+/- cells (lanes #5 & 6) (Fig. 6A). The HIF-1/DNA com-
plex was up-shifted in the presence of the HIF-1α anti-
body (Fig. 6A). The EMSA and supershift assay results
provide the evidence that HIF-1 physically interacts with
the consensus HIF-1-binding sequence under hypoxic
conditions or CoCl2 treatment.
To further demonstrate the interaction of HIF-1α with
HIF-1-binding DNA sequence, the HIF-1-binding
sequence from the promoter region of MCP-1 gene or a
mutant sequence was cloned into a luciferase reporter
gene vector. The constructs were transfected into FHAs
cells, which were then subjected to normoxia or hypoxia
for 4 h. The luciferease activity from the cells transfected
with either an empty or mutant vector did not show sig-
nificant change under normoxic or hypoxic conditions
(Fig. 6B). However, the luciferase reporter activity from
the cells transfected with pGL3/MCP1w was significantly
increased during hypoxia (p < 0.05) compared to the con-
trols (Fig. 6B). The reporter gene assay results demonstrate
that HIF-1 interacts with the HIF-1-binding sequence in
MCP-1 gene and activates MCP-1 transcription in FHAs
exposed to hypoxia.
Discussion
The data presented above suggest that both MCP-1 and
MCP-5 are HIF-1 target genes. This is illustrated by the
presence of HIF-1-binding sites in their promoter regions,
the up-regulation by hypoxia and cobalt chloride, and the
general correlative relationship between HIF-1α and the
levels of MCP-1 and MCP-5 in astrocytes. Up-regulation
of MCP-1 and MCP-5 by HIF-1α in astrocytes exposed to
hypoxia, similar to that observed for IL-1β, EPO, VEGF
and others [11-14,20], is likely an adaptive response to
hypoxic environment; however, HIF-1α-mediated up-reg-
ulation of inflammatory mediators also initiates an
inflammatory process. Infiltration of peripheral inflam-
matory cells into the brain is a critical step in the develop-
ment and progression of the neuroinflammation evoked
by hypoxia/ischemia [1-3]. Chomokines (including MCP-
1, MCP-5, IL-8, GRO, etc) produced by astrocytes and
other cell types in response to hypoxia/ischemia play a
central role in the inflammatory process by forming a che-
moattractant gradient that attracts blood-borne inflam-
matory cells (neutrophils, monocytes and macrophages)
to transmigrate across the blood-brain barrier into the
brain [32-39]. Both MCP1 and MCP-5 are potent chemok-
ines selective for monocytes and macrophages [29,32]. In
vivo  studies have shown that infiltrating blood-borne
monocytes and macrophages were recruited into the
ischemic tissue as early as 18 h following a transient mid-
dle cerebral artery occlusion (MCAO) in mice
[32,35,36,39]. The infiltration peaked at 48 h and
remained abundant at 96 h after MCAO. Furthermore,
Table 2: HIF-1 binding sites in the promoter regions of MCP-1 and MCP-5 genes
MCP-1: GenBank Accession # AY357296
5'-GACCATCCAAGCAGACGTGGTA CCCACAGTCT TGCTTTAACG CTACTTTTCC AAGATAAGGT GACTCAGAAA AGGACAAGGG 
GTGAGCCCAA CCACACAGCTGC-3'
MCP-5: GenBank Accessions # AC012294, NC_000077
5'-AAACACAGCTTAAAATAAAACAAAGAGGACGTGAGG-3'
5'-CAACTACAGAATCGGCGTGTGCCA-3'
5'-TCACGTGCTGTTATAATGTTGTTAAGCAGAAGATTCACGTCC-3'Journal of Neuroinflammation 2007, 4:12 http://www.jneuroinflammation.com/content/4/1/12
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Effects of in vitro hypoxia on the expression of mouse HIF-1α in HIF-1α+/- and HIF-1α+/+ astrocytes Figure 1
Effects of in vitro hypoxia on the expression of mouse HIF-1α in HIF-1α+/- and HIF-1α+/+ astrocytes. Confluent astrocyte mon-
olayers of both cell types were exposed to a 6 h in vitro hypoxia. HIF-1α mRNA expression was determined by RT-PCR as 
described in Materials and Methods. Each bar represents the mean ± SD of relative density/volumes of the bands on film nega-
tives from at least three experiments. Asterisks and number sign indicate significant difference (p < 0.01; one-way ANOVA, fol-
lowed by multiple comparisons among means).
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Effects of in vitro hypoxia on MCP-5 expression in mouse HIF-1α+/- and HIF-1α+/+ astrocytes Figure 2
Effects of in vitro hypoxia on MCP-5 expression in mouse HIF-1α+/- and HIF-1α+/+ astrocytes. The cells were exposed to a 6 h in 
vitro hypoxia. MCP-5 mRNA expression and immunoreactive protein secretion were determined by RT-PCR (A) and ELISA 
(B), respectively, as described in Materials and methods. Each bar represents the mean ± SD of relative density/volumes of the 
bands on film negatives from at least three experiments or three ELISA assays. Asterisks and number signs indicate significant 
difference compared to relevant controls (p < 0.01; one-way ANOVA, followed by multiple comparisons among means).
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Effects of CoCl2 treatment on HIF-1α expression in mouse astrocytes Figure 3
Effects of CoCl2 treatment on HIF-1α expression in mouse astrocytes. (A) The cells were incubated in the presence or 
absence of 125 μM CoCl2 for 6 hr. HIF-1α mRNA expression was determined by RT-PCR. Each bar represents the mean ± SD 
of relative density/volumes of the bands on film negatives from at least three experiments. Asterisk and number sign indicate 
significant difference compared to relevant controls (p < 0.01; one-way ANOVA, followed by multiple comparisons among 
means). (B) Western blots using nuclear proteins show that both hypoxia (H) and CoCl2 (Co) up-regulated HIF-1α protein in 
HIF-1α+/+ and HIF-1α+/- cells. There was no HIF-1α protein detected in control cells (C).
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Effects of CoCl2 treatment on MCP-5 expression in mouse HIF-1α+/- and HIF-1α+/+ astrocytes Figure 4
Effects of CoCl2 treatment on MCP-5 expression in mouse HIF-1α+/- and HIF-1α+/+ astrocytes. The cells were incubated in the 
presence or absence of 125 μM CoCl2 for 6 hr. MCP-5 expression at the mRNA and protein levels was determined by RT-PCR 
(A) and ELISA (B), respectively. Each bar represents the mean ± SD of relative density/volumes of the bands on film negatives 
from least three experiments or three ELISA assays. Asterisks and number signs indicate significant difference compared to rel-
evant controls (p < 0.01; one-way ANOVA, followed by multiple comparisons among means).
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Effects of hypoxia or CoCl2 treatment on MCP-1 expression in fetal human astrocytes (FHAs) Figure 5
Effects of hypoxia or CoCl2 treatment on MCP-1 expression in fetal human astrocytes (FHAs). MCP-1 mRNA expression and 
immunoreactive protein in FHAs exposed to hypoxia or 125 μM CoCl2 for 4 h were determined by RT-PCR (A) and ELISA (B), 
respectively, as described in Materials and methods. Panel A shows that four dishes of cells were used per treatment, and four 
RT-PCR reactions per treatment were therefore carried out. Each bar represents the mean ± SD of relative density/volumes 
of the bands on film negatives from least three experiments or three ELISA assays. Asterisks indicate significant difference com-
pared to relevant controls (one-way ANOVA, followed by multiple comparisons among means; p < 0.01 for Panel A, p < 0.05 
for Panel B).
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Effects of hypoxia or CoCl2 treatment on HIF-1 DNA binding and reporter gene activity in astrocytes Figure 6
Effects of hypoxia or CoCl2 treatment on HIF-1 DNA binding and reporter gene activity in astrocytes. (A) Mouse HIF-1α+/+ 
and HIF-1α+/- cells were exposed to hypoxia or 125 μM CoCl2 for 6 h, nuclear extracts were then prepared and EMSA carried 
out as described in the Materials and Methods. HIF-1 in the nuclear extracts isolated from hypoxia or CoCl2-treated cells 
bound to the wild-type probe (lanes #1–6) but not to the mutant probe (lanes #7–12). HIF-1/DNA complex was detected in 
hypoxia (H)-or CoCl2 (Co)-treated cells (lanes #2, 3, 5, 6) but not in control (C) cells (lanes #1, 4). More complex (darker 
band) was seen in hypoxia-or CoCl2-treated HIF-1α+/+ cells (lanes #2, 3) than that in hypoxia-or CoCl2-treated HIF-1α+/- cells 
(lanes #5, 6). Supershift assay showed that the HIF-1/DNA complex was shifted up in the presence of wild-type (wt) oligo 
probe and 4 μg HIF-1α antiboby (lanes #13 & 14). (B) The activity of the reporter gene, luciferase yellow, under a wild-type 
HIF-1-binding sequence from MCP-1 promoter (pGL3/MCP1w) or a mutated sequence (pGL3/MCP1m), was carried out to 
test the transcriptional activation of MCP-1 by HIF-1 activated by hypoxia. FHAs were transfected with an empty vector, pGL3/
MCP1w or pGL3/MCP1m, respectively, and recovered overnight for 16 h. The cells were exposed to normoxia or hypoxia for 
4 h and then harvested for luciferase yellow assays. Hypoxia strongly stimulated the reporter gene activity from pGL3/MCP1w 
but not from the empty vector and pGL3/MCP1m. Each bar represents the mean ± SD of three assays and each assay had at 
least two replicates. Asterisks indicate significant difference compared to relevant controls (p < 0.05, one-way ANOVA, fol-
lowed by multiple comparisons among means).
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anti-MCP-1 gene therapy attenuated infarct volume and
infiltration of inflammatory cells in focal brain ischemia
of hypertensive rats [38]. Astrocytes are main cytokine/
chemokine-producing cells in the brain [34,37], and
astrocyte-produced MCP-1 directs the transmigration of
monocytes and macrophages across the BBB to the sites of
axonal injury in the brain [33,37]. Both in vitro and in vivo
findings suggest that hypoxia/ischemia-induced infiltra-
tion of monocytes and macrophages contributes to the
pathophysiology and damage induced by stroke.
Up-regulation of inflammatory genes by hypoxia/
ischemia may be regulated by different transcription fac-
tors at different stages of the inflammation, including
HIF-1, NFκB, and AP-1 [3,8,10,40]. The evidence pro-
vided in this study and an previous work [11] established
that HIF-1 induces transcriptional up-regulation of
inflammatory cytokines and chemokines during hypoxia;
whereas NFκB is mainly involved in transcriptional regu-
lation of these genes during the phase of reoxygenation
[8,40]. The temporal interplay of these transcription fac-
tors may be critical in the regulation of inflammatory gene
expression at different stages of hypoxia/ischemia-evoked
inflammation. Targeting transcriptional regulators of
inflammatory genes may help tune the inflammatory
response. Neuroinflammation following brain ischemic
damage is an important part of damage resolution process
by which macrophages remove dead cells and inflamma-
tory mediators stimulate multipotent cells to differentiate
to functional neuronal or glial cells in the injured area [1-
3,42]. MCP-1 has been shown to induce migration of rat-
derived adult neural stem cells in an in vitro model of
brain inflammation [43]. Tuning of MCP-1 levels at differ-
ent stages of the inflammation associated with ischemic
brain damage may maximize the benefit effects of the
inflammation. The evidence of HIF-1α-mediated up-regu-
lation of MCP-1 and MCP-5 during hypoxia suggests that
HIF-1  may be a target for the regulation of inflamma-
tory chemokines in the neuroinflammation induced by
hypoxia/ischemia. However, it should be noted that the
observations from this in vitro study may not be entirely
extrapolated to the in vivo situations since the in vitro and
in vivo responses of astrocytes to hypoxia/ischemia may
not be identical. Further in vivo studies are needed to vali-
date the in vitro observations.
Conclusion
This study has identified HIF-1-binding sites in the pro-
moter regions of MCP-1 and MCP-5 genes. Hypoxia and
CoCl2 up-regulate the expression of both HIF-1α and
chemokines MCP-1 and MCP-5 in astrocytes. The levels of
MCP-5 up-regulation induced by hypoxia or CoCl2 corre-
lated with the levels of hypoxia-stimulated HIF-1α in
mouse astrocytes. HIF-1 protein complex activated by
hypoxia binds to the HIF-1-binding DNA sequence as
shown by EMSA and activates MCP-1 transcription as
demonstrated by reporter gene assay, respectively. These
findings suggest that HIF-1 is involved in transcriptional
regulation of hypoxia-upregulated expression of chemok-
ines MCP-1 and MCP-5 in astrocytes.
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